Spravato vs. Compounded Ketamine: Cost, Coverage, Effectiveness (2026)

If you're researching ketamine therapy in 2026, you'll encounter two fundamentally different products that share the same underlying drug class: Spravato, the FDA-approved esketamine nasal spray administered in certified clinics, and compounded ketamine, the off-label racemic formulation prescribed for at-home use by telehealth physicians. Both work. They are not interchangeable, and the right one for you depends on insurance, severity, geography, and how much of your life you can structure around treatment.

I prescribe compounded racemic ketamine sublingually for at-home use in Florida and New Jersey, and I refer patients to Spravato when their case fits that pathway better. This is the honest comparison, not the marketing one.

The five-minute summary

What's actually in each one

Spravato (esketamine)

Spravato is the trade name for esketamine — purified S-ketamine, just one of the two mirror-image forms of the ketamine molecule. Janssen developed it specifically for treatment-resistant depression and got FDA approval in 2019, with a second indication (MDD with acute suicidal ideation) added in 2020. It's the only FDA-approved ketamine product for depression in the United States.

S-ketamine binds NMDA receptors roughly 3 to 4 times more tightly than R-ketamine, which means a smaller milligram dose produces equivalent dissociative and antidepressant effects. The clinical trial program that supported FDA approval (TRANSFORM-1, -2, -3 and SUSTAIN-1, -2) demonstrated efficacy in TRD across multiple cohorts.

Compounded racemic ketamine

When physicians prescribe "ketamine" off-label for psychiatric indications, they almost always mean racemic ketamine — the standard 50/50 mixture of S- and R-enantiomers that has been in continuous medical use since 1970. Anesthesia, emergency medicine, and pediatric procedural sedation have used racemic ketamine for half a century with a well-characterized safety profile.

For at-home psychiatric use, racemic ketamine is dispensed by a U.S.-licensed compounding pharmacy as a sublingual troche (held in the mouth and dissolved over 10–15 minutes) or rapid-dissolve tablet (RDT/ODT). Bioavailability is roughly 25–35% by the sublingual route, which is why the dose is adjusted upward versus IV protocols. For more on the formulation differences, see our guide to ODT vs troche.

The mechanism question — does the enantiomer matter?

This is the clinical debate that won't quite die. Multiple preclinical studies, mostly from Kenji Hashimoto's group in Japan, suggested that R-ketamine (arketamine) might drive longer-lasting antidepressant effects with less dissociation than S-ketamine — potentially making racemic or pure-R formulations more clinically valuable than pure-S Spravato.

The PCN-101 Phase 2a trial in 2023 was designed specifically to test this hypothesis in humans with TRD. The result: PCN-101 (pure R-ketamine) failed to separate from placebo on the primary endpoint. That doesn't disprove R-ketamine as an antidepressant, but it means the "pure R is better" hypothesis no longer has supporting human Phase 2 evidence. For a deeper dive on the enantiomer question, see R vs S ketamine.

The practical takeaway in 2026: at therapeutic doses delivered through the right route in the right setting, S-only (Spravato) and racemic (compounded) ketamine produce comparable real-world response rates for TRD — roughly 60–75% across published cohorts. The choice between them is mostly about access, cost, and logistics, not which enantiomer your dose contains.

Cost — the variable that actually decides for most patients

What Spravato actually costs

Spravato's wholesale acquisition cost is roughly $590–$900 per session at standard induction dosing (56–84 mg). The clinic adds facility fees, REMS-mandated nursing observation time, and physician supervision charges, which typically push the cash-pay cost to $800–$1,200 per session. The standard induction protocol is twice-weekly sessions for 4 weeks (8 sessions), then weekly for 4 weeks (4 more), then biweekly maintenance — a typical first-year cash-pay cost of $14,000–$24,000.

If your insurance approves Spravato (which requires prior authorization, documented failure of two adequate antidepressant trials, and ongoing utilization review), copays typically run $150–$300 per session. Some commercial plans cover it well; some Medicaid plans cover it; Medicare Part B covers it under specific conditions. Approval rates have improved since launch but remain inconsistent — and an approved patient can lose coverage at any utilization-review checkpoint.

What compounded ketamine actually costs

Compounded ketamine is essentially never covered by insurance for psychiatric indications. It's an off-label compounded preparation, and U.S. health plans don't cover off-label compounded use of any drug. So the cash-pay cost is what you pay.

For at-home programs, the typical 2026 cost structure is a clinical care fee from the prescribing program ($129–$1,000+/month depending on the program — Joyous at the low end, Nue Life at the high end, Discreet Ketamine at $250) plus pharmacy medication cost ($75–$150/month at therapeutic doses, billed separately by the compounding pharmacy). A typical first-year out-of-pocket cost runs $3,000–$12,000 across the at-home program landscape.

The math, in one comparison

For a patient with no insurance coverage for Spravato (the majority outcome), comparing one year of treatment:

• Spravato cash-pay: $14,000–$24,000
• Discreet Ketamine compounded sublingual: $3,000–$5,000 (clinical + medication for a year)

That's roughly a 4-to-6× cost difference for comparable real-world response rates. This is the math that drives most of the at-home compounded ketamine market.

For patients whose insurance does cover Spravato fully, the calculus reverses — Spravato becomes the cheaper option, and the FDA-approved pathway is preferable for documentation and continuity of care reasons. Always check coverage before deciding.

What clinic time and logistics actually involve

Spravato in practice

Spravato administration follows a specific protocol mandated by the REMS (Risk Evaluation and Mitigation Strategy) program:

1. Arrive at a certified Spravato clinic
2. Self-administer the nasal spray under direct nursing supervision
3. Remain in the clinic for at least 2 hours of monitoring (BP, dissociation, sedation)
4. Cannot drive home — arrange transportation
5. The full visit takes 3–4 hours including clinic logistics

Across an induction course (12 sessions over 2 months), that's 36–48 hours of clinic time. For working adults, that's a substantial scheduling burden.

Compounded ketamine in practice

At-home compounded ketamine sessions follow a different rhythm:

1. Pre-session prep at home (4-hour fast, quiet space, music, eye mask)
2. Take the sublingual troche or ODT, hold under tongue for 10–15 minutes
3. Lie still through the 60–90 minute experience
4. Stay home for at least 4 hours total (no driving, no work)
5. The session is in your own space; no clinic, no waiting room, no transportation needed

The medication itself ships from a U.S.-licensed compounding pharmacy in 2–3 days. Across a 6-session induction at home, the total time investment is roughly 24–36 hours, all in your own environment.

Who should choose which

Spravato is the better fit when:

• Your insurance covers it (especially with low copays)
• You have treatment-resistant depression and want the FDA-cleared pathway for documentation purposes
• You're in acute suicidal crisis where a 24-hour response is clinically decisive
• You have geographic access to a certified Spravato clinic
• Your medical complexity (cardiovascular history, recent MI, etc.) warrants clinic-based monitoring during sessions
• You prefer the clear, structured experience of being treated in a medical setting

Compounded sublingual ketamine is the better fit when:

• Insurance won't cover Spravato (the typical case for cash-pay patients)
• Cost-per-session is the binding constraint
• Your work or family schedule can't accommodate repeated multi-hour clinic visits
• You live far from a Spravato-certified clinic
• You're clinically stable enough for at-home administration
• You value privacy and the at-home setting (especially for first responders, veterans, professionals concerned about visibility)
• You're transitioning to long-term maintenance and want the lower per-session cost

Worth noting:

Many patients use both modalities sequentially. A common pathway is Spravato in a clinic for acute stabilization (when insurance covers it) followed by transition to at-home compounded for maintenance once the acute phase has resolved. The two systems can coordinate when both providers communicate.

Frequently Asked Questions

Is Spravato more effective than compounded ketamine?

Not in any clear-cut way. Real-world response rates for treatment-resistant depression land at roughly 60–75% for both Spravato and compounded racemic ketamine when used in appropriate clinical contexts. The FDA-approved status of Spravato reflects the regulatory completion of its clinical trial program, not a clinical superiority over off-label compounded use. The bigger variables are formulation, setting, integration support, and patient adherence.

Why is Spravato so expensive compared to compounded ketamine?

Three reasons. First, the drug itself carries a brand-pharmaceutical price tag rather than a compounded-pharmacy price. Second, the REMS program requires a 2-hour clinic monitoring period after each dose, with associated facility, nursing, and physician fees. Third, the certified-clinic infrastructure (specialized BP monitoring, dissociation assessment, secure storage) adds operational cost. Compounded sublingual ketamine eliminates all three cost drivers but trades that for off-label status.

Does insurance cover Spravato but not compounded ketamine?

Generally yes. Spravato is FDA-approved with established billing codes, so insurance coverage is structurally possible (though not automatic — prior authorization is typically required). Compounded ketamine is off-label and dispensed by a compounding pharmacy, neither of which insurance carriers reimburse for psychiatric indications. The exceptions are extremely rare.

Can you switch from Spravato to compounded ketamine?

Yes, and it's a common pathway. Patients who begin with Spravato for acute stabilization often transition to compounded sublingual maintenance once they're past the crisis phase. The handoff works when both providers communicate. Pharmacokinetically, the at-home sublingual dose is started at the standard new-patient level rather than scaled directly from the Spravato dose, since bioavailability differs significantly between routes.

Is compounded ketamine legal?

Yes, when prescribed by a licensed physician operating in a state where they're licensed to prescribe controlled substances, dispensed by a U.S.-licensed compounding pharmacy, and used for a documented medical indication. Off-label prescribing is a standard, legal part of medicine — roughly 20% of all prescriptions are off-label. The illegitimate sources are offshore pharmacies and gray-market suppliers. See our physician's checklist for evaluating online ketamine clinics.

How do response rates compare?

Across published clinical and real-world data, response rates for treatment-resistant depression run roughly 60–70% for Spravato and 60–75% for compounded racemic ketamine (varying by route, dose, and patient cohort). The differences are within population variance — small enough that the modality choice should be driven by access, cost, and clinical fit rather than expected efficacy difference.

Does the VA cover Spravato or compounded ketamine?

The VA covers Spravato at certified VA medical facilities for treatment-resistant depression in some cases, with eligibility criteria and prior authorization. The VA does not cover at-home compounded ketamine. Veterans seeking compounded ketamine typically pay out-of-pocket using HSA/FSA funds (medical expense eligible) or service-connected disability income. See our Florida veterans page for more.

Is Spravato safer than compounded ketamine?

In specific operational senses, yes — the REMS program ensures continuous monitoring during the highest-risk window (the first 2 hours after dose), with emergency-response capability immediately available. Compounded sublingual ketamine is administered at home with remote physician oversight, which substitutes rigorous patient screening and slower drug absorption for in-room monitoring. For appropriately screened patients, both settings are safe. The relative-risk math favors Spravato for medically complex cases and compounded for stable outpatients.

The bottom line

Spravato and compounded ketamine are not competitors so much as complementary options serving different patient situations. If your insurance covers Spravato well and clinic access works for your life, that's the FDA-approved pathway and a reasonable first choice. If you're paying out-of-pocket, can't access a certified clinic, or are transitioning to long-term maintenance, compounded sublingual ketamine through a careful at-home program is clinically sound and financially sustainable.

What matters more than the modality choice is whether your provider — Spravato clinic or compounded ketamine telehealth — is operating with rigorous medical screening, transparent pharmacy disclosure, and continuity of care. If you want the framework for evaluating any provider, see our physician's checklist for online ketamine clinics.

If you're in Florida or New Jersey and want to know whether at-home compounded ketamine is appropriate for your case, the five-minute eligibility check is the start. If your clinical situation is a better fit for Spravato or another setting, I'll say so.